NOVETUDE SANTE acquired by CHARTERHOUSE

Structured as a leveraged buyout (LBO), the transaction announced on November 12, 2020, enables Charterhouse Capital Partners LLP to acquire a controlling stake in Novetude Santé from BIM, the France-based investment company headed by Robert Zolade. The transaction marks a new partnership between two parties with a long-standing history, as Charterhouse was previously a shareholder in Elior between 2006 and 2014. Under the finalized transaction framework marking the first leveraged buyout in the corporate history of Novetude Santé, the executive management team actively reinvests alongside Charterhouse Capital Partners LLP, retaining an equity shareholding to maintain operational leadership continuity. At the time of this ownership transition, Novetude Santé recorded annual revenue of €37M across its specialized educational operations. Strategically, Charterhouse Capital Partners LLP identifies Novetude Santé as an attractive consolidation platform within the fragmented healthcare education landscape. The sponsorship program focuses on supporting the executive leadership of Novetude Santé in executing an external growth roadmap, deploying capital resources to finance selective add-on acquisitions and accelerate internationalization across European markets. Through this institutional backing, Charterhouse Capital Partners LLP leverages its established buy-and-build experience to scale the operational scope of Novetude Santé and systematically integrate new academic organizations. For the historical shareholder BIM, directed by Robert Zolade, this capital transaction concludes an initial development phase following the founding of Novetude Santé. To complete the acquisition, Charterhouse Capital Partners LLP retained an extensive advisory syndicate: commercial due diligence was performed by EY-Parthenon, financial and tax advisory mandates were conducted jointly by Eight Advisory and Mayer Brown, while HPML provided corporate legal counsel.